Zevra Therapeutics (ZVRA) Shares Outstanding (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Shares Outstanding (Entity) data on file, last reported at $60.7 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 7.88% year-over-year to $60.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.7 million (up 7.88% YoY) and the FY2025 annual result came in at $58.3 million, up 5.6% from the prior year.
• Shares Outstanding (Entity) improved to $60.7 million in Q1 2026, from $58.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $60.7 million in Q1 2026 to a low of $35.3 million in Q1 2022.
• A 5-year average of $45.4 million and a median of $43.4 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) surged 84.54% — and 2023, when it grew 0.01%.
• Tracing ZVRA's Shares Outstanding (Entity) over 5 years: stood at $35.5 million in 2022, then gained by 0.01% to $35.5 million in 2023, then soared by 55.83% to $55.2 million in 2024, then climbed by 5.6% to $58.3 million in 2025, then climbed by 4.03% to $60.7 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $60.7 million (Q1 2026), $58.3 million (Q4 2025), and $57.8 million (Q3 2025), per Business Quant data.